Time: 13:10

Interview

New research centre in Queensland

The University of Queensland has launched a new $7 million regenerative medicine research centre with the aim of improving the quality of life of senior Australians. Queensland Premier Annastacia Palaszczuk launched the UQ Centre in Stem Cell Ageing and Regenerative Engineering (UQ-StemCARE) at the university’s Australian Institute for Bioengineering and Nanotechnology. UQ-StemCARE will focus on identifying and … Continue reading New research centre in Queensland

Australia must do more to build ‘true innovation eco-system’

Teva Pharma is the world’s largest generics company but there is much more to Teva in Australia, according to managing director John Michailidis. Mr Michailidis was appointed to lead the Israel-based company’s Australian and New Zealand commercial operation in August 2014. He was its first employee, but now leads a commercial organisation of over 45. In addition, approximately … Continue reading Australia must do more to build ‘true innovation eco-system’

‘A match made in heaven’

Industry has had to change its approach to innovation as the world becomes more inter-connected, according to Seema Kumar, Vice President, Innovation, Global Health, and Policy Communication, Johnson & Johnson. Kumar spoke to BiotechDispatch in advance of giving a keynote address on ‘deepening trust and engagement’ to the Corporate Affairs Summit in Sydney. She is responsible for … Continue reading ‘A match made in heaven’

Ferris: Time to focus on the ‘D’ in R&D

BiotechDispatch spoke with Bill Ferris AC after his briefings on the $500 million Biomedical Translation Fund. Mr Ferris was appointed the chair of Innovation Australia last year, now Innovation and Science Australia. He founded Australia’s first venture capital company in 1970 and is currently co-chairman of CHAMP Equity, the Sydney-based firm he started in 2000. He is a … Continue reading Ferris: Time to focus on the ‘D’ in R&D

‘We only get a certain number of neurons’

BiotechDispatch recently spoke with Dr Darryle Schoepp, Vice President and Neuroscience Discovery Therapeutic Area Leader for MSD’s global research organisation. Dr Schoepp was in Australia to participate in a symposium in Adelaide on drug discovery and development for cognition and Alzheimer’s disease. The symposium was part of the company’s collaboration with leading Australian biotechnology company, Bionomics. Dr Schoepp addressed … Continue reading ‘We only get a certain number of neurons’

Immune therapies reshaping standard of care

Dr Alan Korman is the Vice President of Immuno-Oncology (I-O) Discovery at Bristol-Myers Squibb Global. He spoke to BiotechDispatch on a recent trip to Australia, during which he met with oncologists and researchers to discuss the company’s I-O portfolio. He trained as a molecular immunologist at Harvard and MIT in Cambridge, Massachusetts, including working with Richard … Continue reading Immune therapies reshaping standard of care

Frazier: Australia could be a dominant power in medicines

In an interview with BiotechDispatch following his address to the Parliamentary Friends of Medicines event in Canberra, Ken Frazier, President and CEO of US-based Merck, one of the world’s largest biopharmaceutical companies and biggest investors in R&D, predicted human biology would be the next great driver of health innovation. According to Frazier, there is an opportunity for Australia to “get … Continue reading Frazier: Australia could be a dominant power in medicines